Holen Sie sich die Stockscreener-App
402.82
0.23%
-0.93
Handel nachbörslich:
404.00
1.18
+0.29%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$403.75
Offen:
$401.71
24-Stunden-Volumen:
2.52M
Relative Volume:
1.05
Marktkapitalisierung:
$152.06B
Einnahmen:
$42.90B
Nettoeinkommen (Verlust:
$6.52B
KGV:
23.63
EPS:
17.05
Netto-Cashflow:
$6.72B
1W Leistung:
+2.33%
1M Leistung:
-5.78%
6M Leistung:
-23.94%
1J Leistung:
-28.42%
1-Tages-Spanne:
$397.31
$405.44
1-Wochen-Bereich:
$397.31
$407.75
52-Wochen-Spanne:
$390.50
$627.88
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Vergleichen Sie TMO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
402.82 | 148.60B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.90 | 132.07B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
513.36 | 40.34B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
111.92 | 30.82B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
140.33 | 23.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
Fetal Bovine Serum Market Detailed in New Research ReportThermo Fisher Scientific, Merck KGaA - openPR.com
Extracellular Matrix Market to Witness Massive Growth by 2032 | - openPR.com
Peptide Synthesis Market Deep Research Report Highlights Key TrendsThermo Fisher Scientific, Merck KGaA - openPR.com
Thermo Fisher Launches New Spectral Flow Cytometer: Stock to Gain? - Yahoo Finance
Thermo Fisher Scientific: Innovative solutions, sustainable choices, and savings for your research journey - Labmate Online
Is Thermo Fisher Scientific Stock Underperforming the Nasdaq? - MSN
Thermo Fisher Must Hand Over Pay Study to Worker Suing for Bias - Bloomberg Law News
Thermo Fisher Scientific launches new Spectral Flow Cytometer - BioSpectrum Asia
Is Thermo Fisher Scientific Stock Underperforming The Nasdaq? - Barchart.com
Ultra-Low Temperature Freezers Market Is Booming WorldwideThermo Fisher Scientific, PHCbi - openPR.com
Thermo Fisher Scientific Launches New Spectral Flow Cytometer Offering Increased Speed, Versatility and Reliability to Labs - BioSpace
Bioinformatics Market Detailed in New Research ReportThermo Fisher Scientific, Illumina - openPR.com
Lentiviral Vectors Market Set to Witness Increased DemandThermo Fisher Scientific, Merck KGaA - openPR.com
Thermo Fisher Scientific Celebrates Precision Oncology Advancement at ASCO 2025 - BioSpace
Thermo Fisher Scientific Stock: Big Upside Potential After Sluggishness Through November? - Benzinga
Biobank Market Deep Research with Forecast By 2025-2032 | Thermo Fisher Scientific Inc., BioLife Solutions - openPR.com
D-Amino Acids Market Report 2025-2030 Featuring Analysis of - GlobeNewswire
Sterilization Monitoring Market Surges Towards USD 1.31 Billion by 2030 Amid Rising Demand for Real-Time Validation - GlobeNewswire Inc.
Spectrometry Market is Booming WorldwideThermo Fisher Scientific, Agilent Technologies - openPR.com
Zacks Investment Ideas feature highlights: Thermo Fisher Scientific and Lululemon - Yahoo Finance
Bioreactors Market Generated Opportunities, Future Scope - openPR.com
Cell-Free DNA Isolation and Extraction Market - GlobeNewswire Inc.
Research Antibodies Market to Witness Remarkable Growth with - openPR.com
Mirai Bio Partners with Thermo Fisher to Integrate AI Design and CGMP Manufacturing for Genetic Medicines - geneonline.com
$1000 Invested In Thermo Fisher Scientific 10 Years Ago Would Be Worth This Much Today - Benzinga
2 S&P 500 Stocks to Buy Now On the Dip for Huge Upside - Yahoo Finance
Thermo Fisher introduces new narcotics analyzers - Wiley Analytical Science
Why Is Thermo Fisher (TMO) Down 6.1% Since Last Earnings Report? - Yahoo Finance
Thermo Fisher makes drug analyzer for law enforcement - The Business Journals
Thermo Fisher Scientific introduces next-generation TruNarc handheld narcotics analyzers - Police1
Cell and Tissue Preservation Market in 2025-2032 Detailed Study - openPR.com
Immune Cell Engineering Market Comprehensive Research Study - openPR.com
Thermo Fisher grants CEO performance-based stock units By Investing.com - Investing.com India
Thermo Fisher grants CEO performance-based stock units - Investing.com
Thermo Fisher Approves CEO’s $60M Stock Award - TipRanks
Thermo Fisher Scientific Grants 5-Year Performance-Based Restricted Stock Units To CEOSEC Filing - marketscreener.com
Thermo Fisher Scientific Inc. (NYSE:TMO) Q1 2025 Earnings Call Transcript - MSN
Thermo Fisher Scientific Introduces Next Generation TruNarc Handheld Narcotics Analyzers to Support Public Safety - BioSpace
Petri Dish: Thermo Fisher’s new partner; Waters buys California company - The Business Journals
Cybin Engages Thermo Fisher Scientific To Provide U.S.-Based Manufacturing for Its CYB003 Program - Technology Networks
Middleton TIF exception created for Thermo Fisher Scientific - MSN
Thermo Fisher Scientific Declares Quarterly DividendMay 21, 2025 - BioSpace
Thermo Fisher Scientific Keeps Quarterly Dividend at $0.43 a Share, Payable July 15 to Investors of Record June 13 - marketscreener.com
Thermo Fisher sets quarterly dividend at $0.43 per share - Investing.com
Thermo Fisher, Mirai Bio link up to advance and produce gene therapies - Fierce Pharma
Mirai Bio announces partnership with Thermo Fisher Scientific - European Pharmaceutical Manufacturer
Middleton approves resolution to support Thermo Fisher Scientific - WKOW
Mirai Bio Announces Strategic Collaboration with Thermo Fisher Scientific - marketscreener.com
Forensics and toxicologyIndustry Focus eBook - News-Medical
Mirai Bio Announces Partnership with Thermo Fisher Scientific to Accelerate Development of Genetic Medicines - PR Newswire
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 - MSN
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):